One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to Mazdutide in 中国. NMPA-approved medicine in China.

Current source route

Mazdutide in 中国

Direct answer / 中国

Can you buy Mazdutide in 中国?

NMPA-approved medicine in China

Mazdutide has NMPA approvals in China for chronic weight management and glycemic control in adults with type 2 diabetes. The exact presentation, current product status, authorization holder, seller identity, and supply route still need to match current Chinese records.

  1. 01
    Resolve the nameClinical pipeline profile
  2. 02
    Check 中国China NMPA medicine approval
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordChina-approved medicine and active clinical program

What Mazdutide resolves to

Mazdutide has NMPA approvals in China for chronic weight management and glycemic control in adults with type 2 diabetes. Those China-specific approvals do not establish FDA approval, authorization in another country, or the identity and authority of an online seller.

Evidence lane
Clinical pipeline profile
Current record
China approvals active; Phase 3 and indication-expansion studies continue
Checked
July 22, 2026
IBI362LY3305677GLP-1/glucagon dual agonist
Destination record必须按具体产品与经营主体分别核验

What 中国 still has to prove

本指南面向在中国搜索肽类、多肽药物、减重药物和研究材料的用户,提供以国家药品监督管理局药品数据和国家企业信用信息公示系统为起点的核验路径。它将具体药品批准、批准持有人、剂型规格、企业登记和网络供应声明分开处理,避免把名称相同、中文页面、人民币价格或境内发货承诺误当成产品已经获批或卖方已经验证的证据。

Comparison mode
人民币 / 药品批准与企业登记记录
Price coverage
暂无符合发布标准的中国卖方价格表
Guide updated
2026年7月18日
Country-specific evidence found2 records attached to this exact check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail